GlaxoSmithKline Pakistan Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PK0001301016
PKR
384.32
6.82 (1.81%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About GlaxoSmithKline Pakistan Ltd. stock-summary
stock-summary
GlaxoSmithKline Pakistan Ltd.
Pharmaceuticals & Biotechnology
GlaxoSmithKline Pakistan Limited is a Pakistan-based pharmaceutical company. The Company is engaged in manufacturing and marketing of research based ethical specialties, other pharmaceutical and consumer products. The Company operates through two segments: Pharmaceuticals and consumer healthcare. The Company's Pharmaceuticals segment includes prescription drugs and vaccines. The Company's consumer healthcare segment includes over-the-counter-medicines, oral care and nutritional care. In Pakistan, the Company deals in anti-infective, respiratory, vaccines, dermatological, analgesics, oncology, urology, central nervous system, allergy, cardiovascular and vitamins therapy areas. The Company's pharmaceutical brands include Augmentin, Seretide, Amoxil, Velosef, Zantac and Calpol, and consumer healthcare brands, which include Panadol, Horlicks, Sensodyne and ENO. Its vaccines include Synflorix, Infanrix Hexa, Rotarix, Havrix and Priorix Tetra.
Company Coordinates stock-summary
Company Details
Sykes Building, 35-Dockyard Road, West Wharf KARACHI None : 74000
stock-summary
Tel: 92 21 32315478
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Dmytro Oliinyk
Non-Executive Chairman of the Board
Mr. Abdul Samad
Chief Financial Officer, Executive Director
Mr. Mark Dawson
Non-Executive Director
Mr. Mehmood Mandviwalla
Non-Executive Director
Mr. Muneer Kamal
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
15,580 Million
(Quarterly Results - Mar 2025)
Net Profit:
2,127 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PKR 122,537 Million (Large Cap)

stock-summary
P/E

15.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

3.90%

stock-summary
Debt Equity

-0.24

stock-summary
Return on Equity

30.90%

stock-summary
Price to Book

4.12